Focus: Molecular Partners is a Swiss-based public biotech company specializing in DARPin® biologics targeting oncology, infectious diseases, and ophthalmology. The company operates a diversified pipeline of early-to-mid stage clinical programs with no marketed products.
Profile data last refreshed 19h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Molecular Partners to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Molecular Partners's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Molecular Partners
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Molecular Partners (NASDAQ: MOLN) sees cash last into 2027 despite H1 2026 loss - Stock Titan
Molecular Partners (NASDAQ: MOLN) sees cash last into 2027 despite H1 2026 loss Stock Titan
Molecular Partners advances DLL3-targeting MP0712 in Phase 1/2a trial, selects CD70 for next radio-DARPin program, reports cash runway into late 2027 - Quiver Quantitative
Molecular Partners advances DLL3-targeting MP0712 in Phase 1/2a trial, selects CD70 for next radio-DARPin program, reports cash runway into late 2027 Quiver Quantitative
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma - The Manila Times
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma The Manila Times
Molecular Partners Develops Two-Target Cancer Radiopharmaceuticals - Stock Titan
Molecular Partners Develops Two-Target Cancer Radiopharmaceuticals Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Wall Street Analysts Are Bullish on Top Healthcare Picks theglobeandmail.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress - Investing.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress Investing.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo